Immunotherapy Coverage from Every Angle

Published Medical Literature

IMpower130 Supports Atezolizumab Inclusion in Stage IV Lung Cancer Therapy
HannaH Trial: Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer
Pinpointing Best Dose of Immunotherapy (AMG 420) in Resistant Myeloma
VALENTINO Study: Comparing Maintenance Therapies in Metastatic Colorectal Cancer
Is Adding Entinostat to Avelumab of Benefit in Treating Advanced Epithelial Ovarian Cancer?
Does Stereotactic Body Radiotherapy Enhance the Effect of Immunotherapy for Lung Cancer?
Melanoma Brain Metastases: Can Nivolumab and Ipilimumab Cross the Blood-Brain Barrier?
First-Line Treatment With Atezolizumab Plus Bevacizumab Versus Sunitinib in Kidney Cancer
CASSIOPEIA Trial: Daratumumab Combination Therapy for Newly Diagnosed Multiple Myeloma
Use of Avelumab in Merkel Cell Carcinoma: Linking Early Response With Overall Survival
Tumor-Infiltrating Immune Cell Characteristics and Recurrence of Clear Cell Kidney Cancer
Meta-analysis of Treatment of Skin Cancers With PD-1/PD-L1 Inhibitors
Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial
Adding Erlotinib to Bevacizumab in EGFR-Positive Lung Cancer
Immune-Related Adverse Events With Nivolumab: Predicting Outcomes in Kidney Cancer
Phase I Study Findings With bb2121 in Resistant Myeloma
Adding Bevacizumab to Carboplatin/Pemetrexed in Nonsquamous NSCLC
Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer
IV Versus IP Chemotherapy Plus Bevacizumab in Advanced Ovarian Cancer
Predicting Response to Immunotherapy for Kidney Cancer With FDG-PET/CT
Correlation Between Blood and Tumor T-Cell Cytotoxicity May Predict Treatment Effectiveness
Combination Therapy May Be Key to Treating KRAS-Mutant NSCLC
First-Line Combination Therapy in Metastatic Kidney Cancer: Answers and More Questions
Viral Vector–Based Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Immunotherapy for Advanced Lung Cancer: Is Tumor Mutational Burden Linked to Response?
Does Squamous Cell Carcinoma Risk Change With Immunosuppression?
Can a Single Dose of PD-1 Inhibitor Before Surgery Predict Outcomes in Melanoma?
KEYNOTE-426 Trial: Pembrolizumab Plus Axitinib Versus Sunitinib in Advanced Kidney Cancer
Nivolumab/Ipilimumab in Advanced Melanoma: Comparison of Dosing Regimens
KAMILLA Trial: T-DM1 Safety in HER2-Positive Breast Cancer
Tisotumab Vedotin Exhibits Antitumor Activity in Bladder Cancer, Among Other Cancers
Treatment With Avelumab in Resistant Ovarian Cancer
Immunotherapy for Patients With NSCLC and HIV Infection
JAVELIN Renal 101 Trial: Axitinib Plus Avelumab in Kidney Cancer
New Combination Therapy for NSCLC Tested in Phase II Trial
Ovarian Carcinosarcoma: Update on a Rare Malignancy
Dasatinib in CML: Activating Natural Killer Cells
Use of Pembrolizumab in First-Line Treatment of Merkel Cell Carcinoma
Tisotumab Vedotin Exhibits Antitumor Activity in NSCLC, Among Other Cancers
Pembrolizumab Versus Platinum-Based Chemotherapy in Advanced NSCLC
Immunotherapy for Patients With Melanoma and HIV Infection
Patient-Reported Outcomes in Advanced Renal Cell Carcinoma
Tisotumab Vedotin Exhibits Antitumor Activity in Ovarian Cancer, Among Other Cancers
Use of Cetuximab in Multimodality Treatment of Cutaneous Squamous Cell Carcinoma
ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide/Dexamethasone in Resistant Myeloma
Study of Combination Immune Checkpoint Blockade in Stage III Melanoma Halted
Neoadjuvant Pembrolizumab Before Surgery in Muscle-Invasive Bladder Carcinoma
Pembrolizumab Plus Chemotherapy in Metastatic Squamous NSCLC
Combination Immunotherapy in First-Line Treatment of Advanced Kidney Cancer
Use of Pembrolizumab for Active Brain Metastases in Patients With Melanoma
Chemosensitivity Mediator and Immunotherapy Target Identified in Ovarian Cancer
Combination Epacadostat and Pembrolizumab in NSCLC
Clinical Benefits of Cetuximab Versus Cisplatin in HPV-Positive Oropharyngeal Cancer
Safety of Daratumumab in Relapsed or Refractory Multiple Myeloma
Combination of Epacadostat and Pembrolizumab in Advanced Melanoma
Durvalumab With or Without Tremelimumab in Subgroup of Resistant Head and Neck Cancer
Atezolizumab in Metastatic Triple-Negative Breast Cancer: Long-Term Outcomes
JAVELIN Lung 200: Avelumab Versus Docetaxel in Advanced Lung Cancer
Pembrolizumab-Associated Dermatomyositis in a Patient With Melanoma
ELOQUENT-2 Trial: Long-Term Benefits of Triplet Therapy in Multiple Myeloma
Alliance Study: Comparing Neoadjuvant Therapy Approaches in HER2-Positive Breast Cancer
Immunotherapy for Stage III Melanoma: Neoadjuvant vs. Adjuvant
Combining TKIs and Immune Checkpoint Inhibitors in Advanced Kidney Cancer
Do Brain Metastases Affect Outcomes With Immunotherapy?
Choosing Among First-Line Treatments in Advanced Kidney Cancer
MAVORIC Results Support FDA Approval of Mogamulizumab in Cutaneous C-Cell Lymphoma
Case Study Highlights Novel Concurrent Therapy for Cutaneous Squamous Cell Carcinoma
Does Following Induction Therapy With Cetuximab Radiotherapy Improve Outcomes in Head and Neck Cancers?
Does Baseline Steroid Use Impact Efficacy of Immunotherapy in Patients With NSCLC?
ASCO Clinical Practice Guidelines Updates in Advanced HER2-Positive Breast Cancer
Update on Nonsurgical Treatments of Non-Melanoma Skin Cancer
Bevacizumab Plus Immune Checkpoint Inhibition in Renal Cell Carcinoma
Neoadjuvant Chemotherapy Plus Panitumumab in Inflammatory Breast Cancer
Are Patients With Chronic Lymphocytic Leukemia at Risk for Melanoma?
ASCO Guideline Update: Adjuvant Chemotherapy and Targeted Therapy for Breast Cancer
Can Patients With Melanoma Benefit From Antigen-Specific Immunotherapeutic?
Review Features Clinical Challenges of Personalized Treatment in NSCLC
Comparing Trastuzumab Biosimilar and Reference Trastuzumab in HER2-Positive Breast Cancer
Immunotherapy in Multiple Myeloma: Today and Tomorrow
Is Ado-Trastuzumab Emtansine Active in HER2-Mutant Lung Cancer?
Closer Look at Therapeutic Interventional Clinical Trials in Multiple Myeloma
Delayed Skin Reactions Reported With PD-1 Inhibitors
Radiosurgery Plus Immunotherapy in Patients With Brain Metastases From Melanoma
Does Prior Antibiotic Use Affect Treatment Outcomes in Lung Cancer?
Combination Pazopanib Plus Cetuximab Therapy Warrants Further Study
Responses to Immune Checkpoint Inhibitors in Patients With NRAS-Mutant Melanoma
Novel Antibody-Drug Conjugate in Platinum-Resistant Ovarian Cancer
New Guidelines for Treating Metastatic Merkel Cell Carcinoma: Focus on Immunotherapy
Intensified Treatment Approach May Improve Survival in Some Patients With Myeloma
First-Line Avelumab for Metastatic Merkel Cell Carcinoma
Who Does Better on Anti–PD-1 Therapy for Melanoma: Younger or Older Patients?
Is Elotuzumab Monotherapy Beneficial in Patients With Smoldering Multiple Myeloma?
Novel Immunotherapy for Poor-Prognosis Relapsed Multiple Myeloma
Study Sheds Light on Dendritic Cell Subsets in Tonsillar Cancer
Baseline Tumor Size and Prognosis in Pembrolizumab-Treated Melanoma
Immune Stimulant in Combination With Nivolumab for Metastatic Lung Cancer
Efficacy of Immunotherapy for Melanoma: Does Gender Matter?
Noninterventional Study of Lenalidomide Plus Dexamethasone in Resistant Myeloma
Treating Nasopharyngeal Carcinoma With Nivolumab
Efficacy of Immunotherapy for Lung Cancer: Does Gender Matter?
Addition of CAR T-Cell Therapy to Stem Cell Transplantation in Refractory Multiple Myeloma
Health-Related Quality of Life With Pembrolizumab for Advanced Urothelial Cancer
Pilot Clinical Trial of Dendritic Cell Vaccination in Ovarian Cancer
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Updated ASCO Guideline for Use of Bone-Modifying Agents in Multiple Myeloma
Comparison of Nivolumab/Ipilimumab and Sunitinib in Advanced Kidney Cancer
DDR Genes and Response to Checkpoint Blockade in Urothelial Cancer
Durvalumab in Heavily Pretreated Patients With Advanced Lung Cancer
PD-1 Blockade in Advanced Desmoplastic Melanoma
Predictor of Response Rates to Anti–PD-1 Therapies Across Cancer Types
Long-Term Survival With Nivolumab in Pretreated Patients With Advanced Lung Cancer
Outcomes When Patients With Melanoma Discontinue Nivolumab/Ipilimumab Combination
Genomic Alterations in Clear Cell Renal Cell Carcinoma and Response to Immune Checkpoint Inhibitors
Denosumab Versus Zoledronic Acid for Treating Myeloma With Bone Disease
Continuation of Immunotherapy Beyond Disease Progression in Advanced Melanoma
Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma
Are Two Monoclonal Antibodies Better Than One in Advanced Melanoma?
Long-Term Survival With Pembrolizumab for Advanced Melanoma
Nivolumab Versus Ipilimumab in Patients With Resected Advanced Melanoma
Does Small Cell Ovarian Cancer Respond to Immunotherapy?
ASPIRE Trial: Triplet Therapy in Relapsed or Refractory Multiple Myeloma
Gene Discovery May Shed Light on Mechanism of Immunotherapy Resistance
Long-Term Outcomes With Atezolizumab in Metastatic Urothelial Carcinoma
Considering Newer Agents in Managing Relapse in Resistant Myeloma
Axitinib Plus Pembrolizumab in Advanced Kidney Cancer
BCMA as a Therapeutic Target and Biomarker in Multiple Myeloma
Dual HER2 Blockade in Metastatic Breast Cancer
Clinical Practice Update on Bone-Modifying Agents in Patients With Multiple Myeloma
Pertuzumab-Containing Neoadjuvant Regimens in HER2-Positive Breast Cancer
Dual HER2-Targeting Treatments for Postmenopausal Women With Metastatic Breast Cancer
Combination Therapy for Previously Untreated Advanced Lung Cancer
Early Research Studies May Advance the Treatment of Multiple Myeloma
Avelumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Effect of Pembrolizumab on Quality of Life for Patients With Advanced Lung Cancer
Novel Antibody Clone for Targeting Multiple Myeloma Cancer Cells
Should Bevacizumab Accompany Adjuvant Chemotherapy in Early-Stage NSCLC?
Long-Term Outcomes With Nivolumab vs. Docetaxel in Advanced Lung Cancer
Safety of Checkpoint Inhibitors Plus Radiotherapy for Metastatic Lung Cancer
Cardiac Effects of Trastuzumab Therapy in Patients With HER2-Positive Breast Cancer
Cost-Effectiveness Comparisons of Treatments for Heavily Pretreated Multiple Myeloma
Can Type of Myeloma Influence Response to Monoclonal Antibodies?
Hair Repigmentation and Response to Immunotherapy for NSCLC
Gene Signature in Predicting Response to Immunomodulatory Derivatives in Myeloma
Are Immune-Related Adverse Events With Nivolumab Linked to Efficacy in NSCLC?
Neoadjuvant Combination Therapy for HER2-Positive Primary Breast Cancer
HER2-Targeted Therapy and Breast Reconstruction
Immunotherapy After Chemoradiotherapy for Stage III Lung Cancer
Post-Progression Response to Nivolumab in Advanced Renal Cell Carcinoma
Adding First-Line Ipilimumab to Chemotherapy for Squamous NSCLC
Prognostic Immune Biomarker in Newly Diagnosed Multiple Myeloma
Neoadjuvant Ado-trastuzumab Emtansine vs. Trastuzumab in Early Breast Cancer
Lenalidomide Maintenance After Transplantation in Multiple Myeloma
Bevacizumab Plus Novel Monoclonal Antibody in Metastatic Kidney Cancer
Response to Immunotherapy in Patients With ‘Claudin-Low’ Breast Tumors
Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma
Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study
Combination Treatment With or Without Transplantation in Multiple Myeloma
Comparing Trastuzumab-Based Regimens in Older Women With Early-Stage Breast Cancer
Thyroid Dysfunction in Patients Receiving Immunotherapy for Advanced Kidney Cancer
Nivolumab in the First-Line Treatment of Advanced or Recurrent Lung Cancer
Pembrolizumab as Second-Line Treatment for Advanced Urothelial Carcinoma
Adding Pertuzumab to Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer
Atezolizumab in PD-L1–Selected Advanced Non–Small Cell Lung Cancer
Cost Analysis of Personalized vs Fixed Dosing of Pembrolizumab
Final Survival Data From TH3RESA Trial in Breast Cancer
Final Overall Survival Data From EMILIA Trial
Early-Phase Trial of Vaccine in NSCLC
Combining Monoclonal Antibodies in HER2-Positive Breast Cancer
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Atezolizumab vs Docetaxel in Patients With Previously Treated NSCLC (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.